DSM-Firmenich AG DSFIR
AmsterdamSpecialty chemicalsFinancials to Sep 30, 2026 · Updated Nov 11, 2026
Moat ranks
Balance sheet
| €B | Dec 31 | Jun 30 |
|---|---|---|
| Cash | 1.8 | 2.3 |
| Securities | 0.1 | 0.0 |
| Debt | 4.8 | 6.8 |
| Net cash | -2.9 | -4.5 |
| Equity | 18.2 | 17.8 |
- Debt / EBITDA
- 4.21×
- Debt / equity
- 0.38×
- Leases (12/31/25)
- €463M
- Diluted shares
- –
- Book value / share
- –
- Price / book
- –
- Net cash / share
- –
- Market cap
- –
- Enterprise value
- –
Per-share record
Key indicators
| Indicator | Latest | Vs year ago | Last 8 halves |
|---|---|---|---|
| Revenue growth | 0.5% | – | – |
| Operating margin | 7.9% | -0.3 pts | |
| FCF margin | 0.8% | +3.1 pts | |
| Capex / revenue | 9.9% | +1.3 pts | |
| Perfumery & Beauty sales (H1) | €1.9B | +2% | |
| Perfumery & Beauty adjusted EBITDA (H1) | €424M | -0% | |
| Perfumery & Beauty organic sales (H1) growth | +7% | – | – |
| Taste, Texture & Health sales (H1) | €1.6B | +0% | |
| Taste, Texture & Health adjusted EBITDA (H1) | €321M | -4% |
Margins and growth from reported quarters; company KPIs as reported in results releases.
About DSFIR
DSM-Firmenich supplies scents, flavours and nutrition ingredients to consumer product makers. Perfumery & Beauty and Taste, Texture & Health benefit from proprietary ingredients, customer-specific application work and a broad formulation portfolio.
- Supply Chain Control
Own production of captive fragrance ingredients helps perfumers create distinctive formulas and secure supply.
- Design In Qualification
Customer briefs draw on the supplier's formulation and application expertise.
- Design In Qualification
Flavours and textures must work in a customer's specific recipe and production process.
- Scope Economies
Combining taste, texture and nutritional ingredients lets the company sell more solutions into an existing customer relationship.
- Nov 4, 2026
dsm-firmenich raised its FY2026 like-for-like sales growth outlook to around 5% from 2–4% after continued volume growth.
- Oct 19, 2026
Shareholders elected Richard Ridinger as chair at the extraordinary general meeting.
- Oct 1, 2026
DSM-Firmenich completed its EUR 540 million buyback, purchasing 7,169,147 shares; EUR 500 million supports capital reduction and EUR 40 million covers employee share plans.
- Sep 29, 2026
The UK CMA confirmed its fragrance investigation involving Firmenich remains open, with its next update due in December. No infringement finding has been made, but regulatory uncertainty remains after the US settlement.
- Sep 16, 2026
DSM-Firmenich expanded Karawang production and opened a shared Jakarta office, bringing its three continuing businesses closer to Indonesian customers.
Ownership
Go deeper on DSFIR
- Compare stock research toolsFundamentals, valuation and screening platforms for DSFIR.19 tools
- See DSFIR's price chartNo price chart here yet. See price history and indicators.17 tools
- Read DSFIR's earnings callsTranscripts and audio of results calls, with management's own words.15 tools
- Investing tool dealsCurrent discounts on research, charting and tracking tools.98 deals
On this page
Financial record
| Fiscal year | 2023 | 2024 | 2025 | TTM | Trend | Change 2023–25 |
|---|---|---|---|---|---|---|
| Per share (€) | ||||||
| Revenue | 45.53 | 34.22 | 34.83 | – | -12.5%/yr | |
| Cash flow | 5.42 | 6.72 | 5.57 | – | +1.4%/yr | |
| Earnings | -2.82 | 1.32 | 1.31 | – | – | |
| Free cash flow | 2.46 | 3.83 | 2.63 | – | +3.4%/yr | |
| Capex | 2.96 | 2.89 | 2.95 | – | -0.3%/yr | |
| Dividends | 2.49 | 2.49 | 2.54 | – | +0.9%/yr | |
| Book value | 98.15 | 85.08 | 70.33 | – | -15.3%/yr | |
| Diluted shares (M) | 233 | 265 | 259 | – | +5.4%/yr | |
| Totals (€B) | ||||||
| Revenue | 10.6 | 9.1 | 9.0 | 9.1 | -7.8%/yr | |
| Operating income | -0.5 | 0.5 | 0.7 | 0.7 | – | |
| Net income | -0.7 | 0.3 | 0.3 | 0.4 | – | |
| Free cash flow | 0.6 | 1.0 | 0.7 | 0.8 | +9.0%/yr | |
| Buybacks | 0.0 | 0.7 | 1.2 | 1.1 | – | |
| Dividends | 0.6 | 0.7 | 0.7 | 0.6 | +6.4%/yr | |
| Net cash | -1.9 | -2.0 | -2.9 | -4.5 | −€1.1B | |
| Margins & returns (%) | ||||||
| Gross margin | 24.6 | 39.2 | 39.1 | 39.2 | +14.5 pts | |
| Operating margin | -4.7 | 6.0 | 7.9 | 7.7 | +12.5 pts | |
| Net margin | -6.2 | 3.8 | 3.8 | 4.2 | +10.0 pts | |
| FCF margin | 5.4 | 11.2 | 7.5 | 9.1 | +2.1 pts | |
| ROIC | -1.4 | 1.6 | 2.3 | 2.2 | +3.7 pts | |
| Return on equity | -2.9 | 1.5 | 1.9 | 2.1 | +4.7 pts | |
| R&D % of revenue | 6.1 | 9.0 | 7.9 | – | +1.8 pts | |
| Stock pay % of revenue | 0.3 | 0.3 | 0.4 | – | +0.1 pts | |
| Capex % of revenue | 6.5 | 8.4 | 8.5 | 9.1 | +1.9 pts | |
Change uses 2023 and 2025 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2023 base. Trend shows the fiscal years.
Moat
Moat scorecard
- Strength
- Confidence
- Structure
- Oligopoly
- Durability
- medium
- Trajectory
- stable
- Pricing power
- moderate
- Perfumery & Beauty30.1%2 claims
- Taste, Texture & Health25.2%2 claims
- Health, Nutrition & Care16.8%1 claim
- Animal Nutrition & Health27.9%1 claim
Moat claims
- Applies to
- Perfumery & Beauty
- Confidence
- Durability
- medium
- Trajectory
- stableas of Jun 30, 2026
Own production of captive fragrance ingredients helps perfumers create distinctive formulas and secure supply. This protection covers proprietary molecules, not every aroma chemical; Aroma Ingredients has moved to the ANH disposal group.
Perfumery & Beauty delivered 7% like-for-like sales growth and 6% like-for-like adjusted EBITDA growth in H1 2026, while proprietary captive molecules continue to support differentiated creations.
- Perfumery & Beauty sales (annual)€3.8B-0%
- Perfumery & Beauty adjusted EBITDA (annual)€815M-3%
- Perfumery & Beauty organic sales (annual) growth+3%
- Perfumery & Beauty sales (H1)€1.9B+2%
- Perfumery & Beauty adjusted EBITDA (H1)€424M-0%
- Perfumery & Beauty organic sales (H1) growth+7%
- Perfumery & Beauty price contribution (H1)0.0%
- Regulatory restrictions on certain fragrance ingredients
- Supply shocks in naturals and key chemical precursors
- Large peers expand vertical integration or secure exclusive feedstocks
- SourceIntegrated Annual Report 2025 - Perfumery & BeautyFeb 20, 2026
- SourceDSM-Firmenich H1 2026 resultsJul 30, 2026
- Source2025 annual report: new captive fragrance molecules manufactured at La PlaineFeb 20, 2026
- SourceSclareol biotechnology patent lawsuit in China; no ruling yetAug 21, 2026
- Applies to
- Perfumery & Beauty
- Confidence
- Durability
- medium
- Trajectory
- stableas of Jun 30, 2026
Customer briefs draw on the supplier's formulation and application expertise. Replacing an established formula requires sensory testing and customer approval, but the company does not disclose a retention rate or a numerical switching cost.
H1 2026 Perfumery & Beauty sales grew 7% like-for-like with higher brief win rates, supporting continued customer demand for its creation platform.
- Perfumery & Beauty sales (annual)€3.8B-0%
- Perfumery & Beauty adjusted EBITDA (annual)€815M-3%
- Perfumery & Beauty organic sales (annual) growth+3%
- Perfumery & Beauty sales (H1)€1.9B+2%
- Perfumery & Beauty adjusted EBITDA (H1)€424M-0%
- Perfumery & Beauty organic sales (H1) growth+7%
- Perfumery & Beauty price contribution (H1)0.0%
- Perfumery & Beauty quarterly sales€1.0B+8%
- Perfumery & Beauty quarterly adjusted EBITDA€223M+8%
- Perfumery & Beauty quarterly like-for-like sales growth+8%
- AI-assisted formulation reduces reliance on supplier application expertise
- Procurement-driven re-bids increase customer switching frequency
- Growth of private label reduces willingness to pay for differentiated creations
- SourceIntegrated Annual Report 2025 - Our approach to businessFeb 20, 2026
- SourceIntegrated Annual Report 2025 - Science & ResearchFeb 20, 2026
- Sourcedsm-firmenich H1 2026 results - Perfumery & BeautyJul 30, 2026
- SourceDSM-Firmenich H1 2026 resultsJul 30, 2026
- Applies to
- Taste, Texture & Health
- Confidence
- Durability
- medium
- Trajectory
- stableas of Jun 30, 2026
Flavours and textures must work in a customer's specific recipe and production process. Application work and sensory validation make replacing an established solution costly, although customers can still use other suppliers for new briefs.
Taste, Texture & Health delivered 4% like-for-like sales growth in H1 2026 and accelerated to 6% in Q2, supporting continued demand for its application work.
- Taste, Texture & Health sales (annual)€3.1B+1%
- Taste, Texture & Health adjusted EBITDA (annual)€648M+4%
- Taste, Texture & Health organic sales (annual) growth+4%
- Taste, Texture & Health sales (H1)€1.6B+0%
- Taste, Texture & Health adjusted EBITDA (H1)€321M-4%
- Taste, Texture & Health organic sales (H1) growth+4%
- Taste, Texture & Health price contribution (H1)0.0%
- Taste Texture & Health quarterly sales€813M+3%
- Taste Texture & Health quarterly adjusted EBITDA€168M+2%
- Taste Texture & Health quarterly like-for-like sales growth+3%
- Customer insourcing of application labs and reformulation work
- Commoditization of some flavor/ingredient components
- Regulatory-driven recipe changes increase re-tendering frequency
- SourceIntegrated Annual Report 2025 - Taste, Texture & HealthFeb 20, 2026
- SourceDSM-Firmenich H1 2026 resultsJul 30, 2026
- Applies to
- Taste, Texture & Health
- Confidence
- Durability
- medium
- Trajectory
- wideningas of Jun 30, 2026
Combining taste, texture and nutritional ingredients lets the company sell more solutions into an existing customer relationship. Reported revenue synergies support this benefit, although they do not prove exclusive customer relationships.
Revenue synergies contributed 1.5 percentage points to Taste, Texture & Health sales growth in H1 2026, showing that the combined portfolio is producing additional sales.
- Taste, Texture & Health sales (annual)€3.1B+1%
- Taste, Texture & Health adjusted EBITDA (annual)€648M+4%
- Taste, Texture & Health organic sales (annual) growth+4%
- Taste, Texture & Health sales (H1)€1.6B+0%
- Taste, Texture & Health adjusted EBITDA (H1)€321M-4%
- Taste, Texture & Health organic sales (H1) growth+4%
- TTH revenue synergy contribution1.5%
- Taste, Texture & Health price contribution (H1)0.0%
- Portfolio complexity increases overhead and slows decision-making
- Customers prefer best-of-breed point suppliers in niche categories
- SourceIntegrated Annual Report 2025 - Our approach to businessFeb 20, 2026
- SourceIntegrated Annual Report 2025 - Taste, Texture & HealthFeb 20, 2026
- Sourcedsm-firmenich H1 2026 results - Taste, Texture & HealthJul 30, 2026
- SourceDSM-Firmenich H1 2026 resultsJul 30, 2026
- Applies to
- Health, Nutrition & Care
- Confidence
- Durability
- medium
- Trajectory
- stableas of Jun 30, 2026
Ingredient approvals, quality controls and supporting safety evidence create an advantage in early-life nutrition and health ingredients. GLYCARE human milk oligosaccharides had approvals in over 170 countries by FY2025; approval alone does not guarantee pricing power.
Health, Nutrition & Care delivered 4% like-for-like sales growth in H1 2026, with strong HMO demand and 15% like-for-like adjusted EBITDA growth.
- Health, Nutrition & Care sales (annual)€2.1B-1%
- Health, Nutrition & Care adjusted EBITDA (annual)€407M+8%
- Health, Nutrition & Care organic sales (annual) growth+3%
- Health, Nutrition & Care sales (H1)€1.0B-1%
- Health, Nutrition & Care adjusted EBITDA (H1)€206M+5%
- Health, Nutrition & Care organic sales (H1) growth+4%
- HMO approved countries≥170
- Health, Nutrition & Care price contribution (H1)1.0%
- Health Nutrition & Care quarterly sales€515M+6%
- Health Nutrition & Care quarterly adjusted EBITDA€114M+4%
- Health Nutrition & Care quarterly like-for-like sales growth+5%
- Regulatory changes increase costs or restrict ingredient claims
- Quality incidents could damage trust and increase audits
- SourceIntegrated Annual Report 2025 - Health, Nutrition & CareFeb 20, 2026
- SourceDSM-Firmenich H1 2026 resultsJul 30, 2026
- SourceFY2025 investor presentation: HMO regulatory access in over 170 countriesFeb 12, 2026
- Applies to
- Animal Nutrition & Health
- Confidence
- Durability
- medium
- Trajectory
- stableas of Jun 30, 2026
Premix facilities and decision-support services connect ingredient sales with customers' production processes. Replacing the supplier can mean replacing those services too.
The premix and services network remains within the planned CVC disposal, while H1 2026 adjusted EBITDA fell 81%; weak vitamin pricing puts funding and separation execution under pressure.
- Animal Nutrition & Health sales (annual)€3.5B-7%
- Animal Nutrition & Health adjusted EBITDA (annual)€507M+38%
- Animal Nutrition & Health sales (H1)€1.5B-19%
- Animal Nutrition & Health adjusted EBITDA (H1)€67M-81%
- Animal Nutrition & Health price contribution (H1)-13.0%
- Service offerings replicated by peers and integrators
- Farm economics downturn reduces willingness to pay for services
- Separation/carve-out disrupts service delivery or investment
- Low vitamin prices compress earnings despite the service layer
- SourceIntegrated Annual Report 2025 - Segment informationFeb 20, 2026
- SourceDSM-Firmenich H1 2026 resultsJul 30, 2026
- SourceEvonik digital tools and analytical animal nutrition servicesOct 6, 2026
- SourceANH divestment agreement with CVCFeb 9, 2026
Profile change log
- Nov 10, 2026 · business change
dsm-firmenich raised its FY2026 like-for-like sales growth outlook to around 5% from 2–4% after continued volume growth.
- Nov 10, 2026 · business change
Shareholders elected Richard Ridinger as chair at the extraordinary general meeting.
- Oct 6, 2026 · analyst revision
The ANH disposal debate now includes the estimated EUR 600 million of net cash proceeds, retained 20% equity stakes and potential financing support. The EUR 2.2 billion headline enterprise value is not the cash DSM-Firmenich expects to receive.
- Oct 6, 2026 · analyst revision
The investment debate now separates the open competition case from restructuring execution and uses the July results release to support the HNC growth argument. Moat strengths and segment weights are unchanged.
- Oct 6, 2026 · business change
The UK CMA confirmed its fragrance investigation involving Firmenich remains open, with its next update due in December. No infringement finding has been made, but regulatory uncertainty remains after the US settlement.
- Oct 6, 2026 · business change
A US court preliminarily approved Firmenich's USD 33 million settlement with direct purchasers in fragrance antitrust litigation. Final approval is pending; Firmenich denies wrongdoing and other legal proceedings continue.
- Oct 6, 2026 · analyst revision
The Perfumery & Beauty and Taste, Texture & Health customer-formulation moats are classified as design and qualification costs. The evidence concerns recipe testing and supplier approval, rather than employee training; claim strengths are unchanged.
- Oct 6, 2026 · business change
DSM-Firmenich completed its EUR 540 million buyback, purchasing 7,169,147 shares; EUR 500 million supports capital reduction and EUR 40 million covers employee share plans.
- Oct 6, 2026 · business change
DSM-Firmenich expanded Karawang production and opened a shared Jakarta office, bringing its three continuing businesses closer to Indonesian customers.
- Oct 6, 2026 · business change
DSM-Firmenich partnered with Boltz to develop exclusive AI models for scent and flavour discovery, adding a route to faster molecule development; commercial gains remain unproven.
- Oct 6, 2026 · business change
DSM-Firmenich sued Chinese entities over biotechnology production of Sclareol, seeking an injunction and damages to protect an ingredient production route; no ruling has been announced.
- Oct 6, 2026 · business change
DSM-Firmenich proposed Richard Ridinger as chairman after Thomas Leysen announced retirement; shareholders vote on October 19.
- Oct 6, 2026 · business change
DSM-Firmenich began trading on SIX alongside Amsterdam, broadening access to Swiss investors.
- Oct 6, 2026 · business change
DSM-Firmenich agreed to sell ANH to CVC for an enterprise value of about EUR 2.2 billion, including an earnout of up to EUR 500 million; retained 20% stakes preserve some exposure.
- Oct 6, 2026 · business change
DSM-Firmenich sold its Feed Enzymes Alliance stake to Novonesis for EUR 1.5 billion, removing the enzyme business and releasing cash.
- Oct 6, 2026 · business change
DSM and Firmenich completed their merger, combining nutrition ingredients with fragrance and flavour creation; Firmenich enters reported results only from the merger date.
- Oct 6, 2026 · analyst revision
Segment weights now use FY2025 restated sales; the six moat claims have sourced trajectories, linked market profiles and operating tests. The supply advantage is limited to proprietary ingredients after Aroma Ingredients moved to ANH.
Industry & peers
Peer map
Peers appear on the map as their numbers are collected.
Global B2B fragrance and beauty ingredients
Fragrance compounds, proprietary scent molecules and active beauty ingredients sold to perfume, personal care and home care manufacturers. This is an ingredient and formulation market; retail perfume and cosmetics sales are excluded.
- Givaudan
- DSM-Firmenich
- IFF
- Symrise
| Stocks | Moat | Gross m. | Op. m. | |
|---|---|---|---|---|
| DSFIR | 68 | 39.2% | 7.7% | |
| Industry median | 11 | 75 | 43.7% | 14.8% |
| Sector median | 14 | 76 | 41.3% | 16.5% |
| All stocks median | 398 | 76 | 53.1% | 20.0% |
Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.
Drivers & risks
- Fine fragrance launches and growing interest in scent increase demand for new customer-specific creations.
- Personal care and home care consumption provides repeat volume alongside the more discretionary fine fragrance business.
- Online commerce and regional fragrance brands create new customer briefs and shorten product launch cycles.
- Natural and biotechnology ingredients create reformulation opportunities and can reduce dependence on scarce natural inputs.
- Consumer caution and customer destocking can reduce ingredient orders even when end-user consumption remains stable.
- Energy, feedstock and natural ingredient costs can rise before contract prices reset; tariffs add sourcing and logistics costs.
- A stronger reporting currency reduces translated sales and profit from global demand; company H1 2026 results show a material FX effect.
- Ingredient restrictions require reformulation, while competition investigations and civil litigation create legal and customer-trust risks.
- Higher interest rates raise the cost of carrying inventories and financing acquisitions for indebted suppliers; weaker consumer demand can extend the time between ingredient purchases and customer payment.
Bulls & bears
Can the three continuing businesses turn customer wins and merger synergies into stronger cash generation after ANH leaves, despite currency pressure and consumer caution?
Arguments
What to watch
- 1Like-for-like sales and price versus volume by continuing business
- 2Taste, Texture & Health revenue synergies and adjusted EBITDA
- 3Continuing operating cash flow and ANH disposal completion
Next check: December 8, 2026 US settlement fairness hearing and December CMA update; ANH closing expected by end-2026; February 18, 2027 results for continuing operations and cash conversion.
Sources: company filings and dated sources collected for Find My Moat; A current closing price and matching share count have not been verified; market cap and valuation multiples are unavailable. Not investment advice.
Free to reuse, commercially too, with a credit link. See the data license.
Moat Score 68/100 by <a href="https://www.findmymoat.com/stocks/XAMS:DSFIR">Find My Moat</a> (as of September 2026)Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.